Open AccessEffects of konjac glucomannan on blood profile in schizophrenia with hyperglycemia
Author(s) -
Sugeng Mashudi,
DianitaRifqia Putri,
Yahya Sulthon Aziz,
Syafira Febi Larasati,
Shiwei Paramita M,
Seftiana Putri Widodo
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns1.4820
Subject(s) - glucomannan , schizophrenia (object oriented programming) , medicine , meal , population , plasma glucose , endocrinology , psychiatry , insulin , pathology , environmental health
Background and Objectives: Konjac glucomannan has the effect of maintaining Blood Glukosa Fasting (BGF) in the general population, but there is no research on schizophrenic patients who are susceptible to hyperglycemia. Our study aims to evaluate the effects of konjac glucomannan on blood glucose levels in schizophrenia in patients with hyperglycemia. Methods and Study Design: eight people with schizophrenia were enrolled in a 30-day pra experimental study. The subjects in the experimental group were given a capsule containing konjac glucomannan 30 minutes before each meal Results: The plasma glucose was measured at baseline and at the first of 0-day treatment end of 31-day treatment. Eight subjects completed the study. There was a substantial decrease in plasma glucose in the experimental group. Conclusions: We concluded that a diet supplemented with konjac glucomannan may prevent the deterioration of hyperglycemia in people with schizophrenia, demonstrating its potential value in the treatment of metabolic disorders in schizophrenia as a new therapeutic method herb.